{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:02:35Z","timestamp":1793858555424,"version":"4.6.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,9,25]],"date-time":"2007-09-25T00:00:00Z","timestamp":1190678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s00213-007-0931-8","type":"journal-article","created":{"date-parts":[[2007,9,24]],"date-time":"2007-09-24T11:53:25Z","timestamp":1190634805000},"page":"303-312","source":"Crossref","is-referenced-by-count":57,"title":["Animal models of Parkinson\u2019s disease and L-dopa induced dyskinesia: How close are we to the clinic?"],"prefix":"10.1007","volume":"199","author":[{"given":"Emma","family":"Lane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Dunnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,9,25]]},"reference":[{"issue":"3","key":"931_CR1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16(3):448\u2013458","journal-title":"Mov Disord"},{"issue":"2","key":"931_CR2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.bbr.2003.12.021","volume":"153","author":"M Alam","year":"2004","unstructured":"Alam M, Schmidt WJ (2004) L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Behav Brain Res 153(2):439\u2013446","journal-title":"Behav Brain Res"},{"issue":"2","key":"931_CR3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0006-8993(92)91584-2","volume":"588","author":"GM Alexander","year":"1992","unstructured":"Alexander GM, Schwartzman RJ, Brainard L, Gordon SW, Grothusen JR (1992) Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Brain Res 588(2):261\u2013269","journal-title":"Brain Res"},{"issue":"3","key":"931_CR4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","volume":"61","author":"W Bara-Jimenez","year":"2003","unstructured":"Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN (2003) Adenosine A(2A) receptor antagonist treatment of Parkinson\u2019s disease. Neurology 61(3):293\u2013296","journal-title":"Neurology"},{"issue":"10","key":"931_CR5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/mds.20124","volume":"19","author":"W Bara-Jimenez","year":"2004","unstructured":"Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN (2004) Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson\u2019s disease. Mov Disord 19(10):1183\u20131186","journal-title":"Mov Disord"},{"issue":"8","key":"931_CR6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","volume":"20","author":"W Bara-Jimenez","year":"2005","unstructured":"Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN (2005) Effects of serotonin 5-HT1A agonist in advanced Parkinson\u2019s disease. Mov Disord 20(8):932\u2013936","journal-title":"Mov Disord"},{"issue":"6","key":"931_CR7","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1212\/WNL.42.6.1241","volume":"42","author":"F Baronti","year":"1992","unstructured":"Baronti F, Mouradian MM, Conant KE, Giuffra M, Brughitta G, Chase TN (1992) Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology 42(6):1241\u20131243","journal-title":"Neurology"},{"key":"931_CR8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1749-6632.1978.tb31507.x","volume":"305","author":"HG Baumgarten","year":"1978","unstructured":"Baumgarten HG, Klemm HP, Lachenmayer L, Bjorklund A, Lovenberg W, Schlossberger HG (1978) Mode and mechanism of action of neurotoxic indoleamines: a review and a progress report. Ann N Y Acad Sci 305:3\u201324","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"931_CR9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","volume":"20","author":"H Bernheimer","year":"1973","unstructured":"Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415\u2013455","journal-title":"J Neurol Sci"},{"issue":"4","key":"931_CR10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/bies.10067","volume":"24","author":"R Betarbet","year":"2002","unstructured":"Betarbet R, Sherer TB, Greenamyre JT (2002) Animal models of Parkinson\u2019s disease. Bioessays 24(4):308\u2013318","journal-title":"Bioessays"},{"issue":"10","key":"931_CR11","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","volume":"57","author":"F Bibbiani","year":"2001","unstructured":"Bibbiani F, Oh JD, Chase TN (2001) Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57(10):1829\u20131834","journal-title":"Neurology"},{"issue":"2","key":"931_CR12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ana.20937","volume":"60","author":"J Bove","year":"2006","unstructured":"Bove J, Zhou C, Jackson-Lewis V, Taylor J, Chu Y, Rideout HJ, Wu DC, Kordower JH, Petrucelli L, Przedborski S (2006) Proteasome inhibition and Parkinson\u2019s disease modeling. Ann Neurol 60(2):260\u2013264","journal-title":"Ann Neurol"},{"issue":"Suppl 3","key":"931_CR13","first-page":"III\/1\u20135","volume":"249","author":"H Braak","year":"2002","unstructured":"Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson\u2019s disease (preclinical and clinical stages). J Neurol 249(Suppl 3):III\/1\u20135","journal-title":"J Neurol"},{"issue":"2","key":"931_CR14","first-page":"343","volume":"231","author":"GR Breese","year":"1984","unstructured":"Breese GR, Baumeister AA, McCown TJ, Emerick SG, Frye GD, Crotty K, Mueller RA (1984) Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther 231(2):343\u2013354","journal-title":"J Pharmacol Exp Ther"},{"issue":"4596","key":"931_CR15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/1801200a0","volume":"180","author":"A Carlsson","year":"1957","unstructured":"Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180(4596):1200","journal-title":"Nature"},{"issue":"3","key":"931_CR16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0022-510X(87)90041-4","volume":"78","author":"CE Clarke","year":"1987","unstructured":"Clarke CE, Sambrook MA, Mitchell IJ, Crossman AR (1987) Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 78(3):273\u2013280","journal-title":"J Neurol Sci"},{"issue":"1","key":"931_CR17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00168809","volume":"338","author":"CE Clarke","year":"1988","unstructured":"Clarke CE, Boyce S, Sambrook MA, Stahl SM, Crossman AR (1988) Behavioural effects of (\u2212)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Naunyn Schmiedebergs Arch Pharmacol 338(1):35\u201338","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"931_CR18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","volume":"179","author":"A Dekundy","year":"2007","unstructured":"Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179(1):76\u201389","journal-title":"Behav Brain Res"},{"key":"931_CR19","first-page":"155","volume":"22","author":"GA Donnan","year":"1986","unstructured":"Donnan GA, Kaczmarczyk SJ, Solopotias T, Rowe P, Kalnins RM, Vajda FJ, Mendelsohn FA (1986) The neurochemical and clinical effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in small animals. Clin Exp Neurol 22:155\u2013164","journal-title":"Clin Exp Neurol"},{"issue":"1\u20132","key":"931_CR20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brainresbull.2005.08.009","volume":"68","author":"E Dowd","year":"2005","unstructured":"Dowd E, Monville C, Torres EM, Dunnett SB (2005) The Corridor Task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Res Bull 68(1\u20132):24\u201330","journal-title":"Brain Res Bull"},{"issue":"4","key":"931_CR21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0306-4522(86)90102-8","volume":"18","author":"E Eidelberg","year":"1986","unstructured":"Eidelberg E, Brooks BA, Morgan WW, Walden JG, Kokemoor RH (1986) Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys. Neuroscience 18(4):817\u2013822","journal-title":"Neuroscience"},{"issue":"4","key":"931_CR22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0022-510X(71)90178-X","volume":"14","author":"S Fahn","year":"1971","unstructured":"Fahn S, Libsch LR, Cutler RW (1971) Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson\u2019s disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 14(4):427\u2013455","journal-title":"J Neurol Sci"},{"issue":"6776","key":"931_CR23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/35006074","volume":"404","author":"MB Feany","year":"2000","unstructured":"Feany MB, Bender WW (2000) A Drosophila model of Parkinson\u2019s disease. Nature 404(6776):394\u2013398","journal-title":"Nature"},{"issue":"1","key":"931_CR24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-8993(97)00008-5","volume":"753","author":"RJ Ferrante","year":"1997","unstructured":"Ferrante RJ, Schulz JB, Kowall NW, Beal MF (1997) Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 753(1):157\u2013162","journal-title":"Brain Res"},{"issue":"1","key":"931_CR25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jneumeth.2005.04.005","volume":"148","author":"MM Ferro","year":"2005","unstructured":"Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME, Canteras NS, Da Cunha C (2005) Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson\u2019s disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 148(1):78\u201387","journal-title":"J Neurosci Methods"},{"issue":"3","key":"931_CR26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1602\/neurorx.2.3.495","volume":"2","author":"SM Fleming","year":"2005","unstructured":"Fleming SM, Fernagut PO, Chesselet MF (2005) Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx 2(3):495\u2013503","journal-title":"NeuroRx"},{"issue":"4","key":"931_CR27","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ana.410200403","volume":"20","author":"LS Forno","year":"1986","unstructured":"Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA (1986) Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 20(4):449\u2013455","journal-title":"Ann Neurol"},{"issue":"10","key":"931_CR28","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/mds.20936","volume":"21","author":"SH Fox","year":"2006","unstructured":"Fox SH, Lang AE, Brotchie JM (2006) Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov Disord 21(10):1578\u20131594","journal-title":"Mov Disord"},{"issue":"2","key":"931_CR29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1345\/aph.1A152","volume":"36","author":"EJ Frackiewicz","year":"2002","unstructured":"Frackiewicz EJ, Jhee SS, Shiovitz TM, Webster J, Topham C, Dockens RC, Whigan D, Salazar DE, Cutler NR (2002) Brasofensine treatment for Parkinson\u2019s disease in combination with levodopa\/carbidopa. Ann Pharmacother 36(2):225\u2013230","journal-title":"Ann Pharmacother"},{"issue":"2","key":"931_CR30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, Rascol O, Russ H (2007) Sarizotan as a treatment for dyskinesias in Parkinson\u2019s disease: a double-blind placebo-controlled trial. Mov Disord 22(2):179\u2013186","journal-title":"Mov Disord"},{"issue":"2","key":"931_CR31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/0006-8993(96)00597-5","volume":"735","author":"R Grondin","year":"1996","unstructured":"Grondin R, Goulet M, Di Paolo T, Bedard PJ (1996) Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res 735(2):298\u2013306","journal-title":"Brain Res"},{"issue":"11","key":"931_CR32","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1046\/j.1460-9568.2003.02685.x","volume":"17","author":"D Guehl","year":"2003","unstructured":"Guehl D, Pessiglione M, Francois C, Yelnik J, Hirsch EC, Feger J, Tremblay L (2003) Tremor-related activity of neurons in the \u2019motor\u2019 thalamus: changes in firing rate and pattern in the MPTP vervet model of parkinsonism. Eur J Neurosci 17(11):2388\u20132400","journal-title":"Eur J Neurosci"},{"issue":"1","key":"931_CR33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/mds.10596","volume":"19","author":"MJ Hansard","year":"2004","unstructured":"Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P (2004) The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates. Mov Disord 19(1):15\u201321","journal-title":"Mov Disord"},{"issue":"3","key":"931_CR34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1046\/j.1471-4159.2003.01533.x","volume":"84","author":"GU Hoglinger","year":"2003","unstructured":"Hoglinger GU, Feger J, Prigent A, Michel PP, Parain K, Champy P, Ruberg M, Oertel WH, Hirsch EC (2003) Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 84(3):491\u2013502","journal-title":"J Neurochem"},{"issue":"4","key":"931_CR35","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1471-4159.2005.03493.x","volume":"95","author":"GU Hoglinger","year":"2005","unstructured":"Hoglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, Feger J, Champy P, Prigent A, Medja F, Lombes A, Oertel WH, Ruberg M, Hirsch EC (2005) The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 95(4):930\u2013939","journal-title":"J Neurochem"},{"key":"931_CR36","doi-asserted-by":"crossref","unstructured":"Hoglinger GU, Oertel WH, Hirsch EC (2006) The rotenone model of parkinsonism\u2014the five years inspection. J Neural Transm Suppl(70):269\u2013272","DOI":"10.1007\/978-3-211-45295-0_41"},{"issue":"1","key":"931_CR37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-0270(99)00184-3","volume":"96","author":"C Imbert","year":"2000","unstructured":"Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE (2000) Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J Neurosci Methods 96(1):71\u201376","journal-title":"J Neurosci Methods"},{"issue":"4","key":"931_CR38","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1460-9568.2005.03915.x","volume":"21","author":"MM Iravani","year":"2005","unstructured":"Iravani MM, Syed E, Jackson MJ, Johnston LC, Smith LA, Jenner P (2005) A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Eur J Neurosci 21(4):841\u2013854","journal-title":"Eur J Neurosci"},{"issue":"2","key":"931_CR39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0014-2999(76)90042-X","volume":"37","author":"ET Iwamoto","year":"1976","unstructured":"Iwamoto ET, Loh HH, Way EL (1976) Circling behavior in rats with 6-hydroxydopamine or electrolytic nigral lesions. Eur J Pharmacol 37(2):339\u2013356","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"931_CR40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","volume":"2","author":"V Jackson-Lewis","year":"2007","unstructured":"Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson\u2019s disease. Nat Protoc 2(1):141\u2013151","journal-title":"Nat Protoc"},{"issue":"1\u20133","key":"931_CR41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-3940(84)90467-1","volume":"50","author":"P Jenner","year":"1984","unstructured":"Jenner P, Rupniak NM, Rose S, Kelly E, Kilpatrick G, Lees A, Marsden CD (1984) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 50(1\u20133):85\u201390","journal-title":"Neurosci Lett"},{"issue":"2","key":"931_CR42","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ana.1051","volume":"50","author":"AE Kingsbury","year":"2001","unstructured":"Kingsbury AE, Cooper M, Schapira AH, Foster OJ (2001) Metabolic enzyme expression in dopaminergic neurons in Parkinson\u2019s disease: an in situ hybridization study. Ann Neurol 50(2):142\u2013149","journal-title":"Ann Neurol"},{"issue":"2","key":"931_CR43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/exnr.1998.6848","volume":"152","author":"D Kirik","year":"1998","unstructured":"Kirik D, Rosenblad C, Bjorklund A (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152(2):259\u2013277","journal-title":"Exp Neurol"},{"issue":"2","key":"931_CR44","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ana.20935","volume":"60","author":"JH Kordower","year":"2006","unstructured":"Kordower JH, Kanaan NM, Chu Y, Suresh Babu R, Stansell J 3rd, Terpstra BT, Sortwell CE, Steece-Collier K, Collier TJ (2006) Failure of proteasome inhibitor administration to provide a model of Parkinson\u2019s disease in rats and monkeys. Ann Neurol 60(2):264\u2013268","journal-title":"Ann Neurol"},{"issue":"1","key":"931_CR45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00001756-200001170-00041","volume":"11","author":"NW Kowall","year":"2000","unstructured":"Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ (2000) MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11(1):211\u2013213","journal-title":"Neuroreport"},{"issue":"6","key":"931_CR46","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/mds.10263","volume":"17","author":"M Kuoppamaki","year":"2002","unstructured":"Kuoppamaki M, Al-Barghouthy G, Jackson M, Smith L, Zeng BY, Quinn N, Jenner P (2002) Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa. Mov Disord 17(6):1312\u20131317","journal-title":"Mov Disord"},{"issue":"1","key":"931_CR47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1460-9568.2004.03834.x","volume":"21","author":"EL Lane","year":"2005","unstructured":"Lane EL, Cheetham SC, Jenner P (2005) Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours. Eur J Neurosci 21(1):179\u2013186","journal-title":"Eur J Neurosci"},{"issue":"2","key":"931_CR48","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.expneurol.2005.06.006","volume":"197","author":"EL Lane","year":"2006","unstructured":"Lane EL, Cheetham SC, Jenner P (2006) Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson\u2019s disease? Exp Neurol 197(2):284\u2013290","journal-title":"Exp Neurol"},{"issue":"2","key":"931_CR49","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0006-8993(84)90777-7","volume":"292","author":"JW Langston","year":"1984","unstructured":"Langston JW, Forno LS, Rebert CS, Irwin I (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 292(2):390\u2013394","journal-title":"Brain Res"},{"issue":"6","key":"931_CR50","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1096\/fj.03-0677fje","volume":"18","author":"N Lapointe","year":"2004","unstructured":"Lapointe N, St-Hilaire M, Martinoli MG, Blanchet J, Gould P, Rouillard C, Cicchetti F (2004) Rotenone induces non-specific central nervous system and systemic toxicity. Faseb J 18(6):717\u2013719","journal-title":"Faseb J"},{"key":"931_CR51","unstructured":"Lewy FH (1914) Zur pathologischen anatomie der Paralysis Agitans. Dtsch. Z. Nervenheilk 1:50\u201355"},{"issue":"7","key":"931_CR52","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/mds.20120","volume":"19","author":"G Linazasoro","year":"2004","unstructured":"Linazasoro G (2004) Recent failures of new potential symptomatic treatments for Parkinson\u2019s disease: causes and solutions. Mov Disord 19(7):743\u2013754","journal-title":"Mov Disord"},{"issue":"1","key":"931_CR53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbr.2006.09.019","volume":"177","author":"HS Lindgren","year":"2007","unstructured":"Lindgren HS, Rylander D, Ohlin KE, Lundblad M, Cenci MA (2007) The \u201cmotor complication syndrome\u201d in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res 177(1):150\u2013159","journal-title":"Behav Brain Res"},{"issue":"3","key":"931_CR54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0031-9384(76)90133-5","volume":"16","author":"T Ljungberg","year":"1976","unstructured":"Ljungberg T, Ungerstedt U (1976) Reinstatement of eating by dopamine agonists in aphagic dopamine denervated rats. Physiol Behav 16(3):277\u2013283","journal-title":"Physiol Behav"},{"issue":"1","key":"931_CR55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","volume":"194","author":"M Lundblad","year":"2005","unstructured":"Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G, Cenci MA (2005) Pharmacological validation of a mouse model of L-DOPA-induced dyskinesia. Exp Neurol 194(1):66\u201375","journal-title":"Exp Neurol"},{"issue":"1","key":"931_CR56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0304-3940(03)00295-7","volume":"343","author":"T Maeda","year":"2003","unstructured":"Maeda T, Kannari K, Shen H, Arai A, Tomiyama M, Matsunaga M, Suda T (2003) Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci Lett 343(1):17\u201320","journal-title":"Neurosci Lett"},{"key":"931_CR57","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1196\/annals.1344.031","volume":"1053","author":"S Mandel","year":"2005","unstructured":"Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, Youdim MB (2005) Gene expression profiling of sporadic Parkinson\u2019s disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci 1053:356\u2013375","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"931_CR58","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.20938","volume":"60","author":"AB Manning-Bog","year":"2006","unstructured":"Manning-Bog AB, Reaney SH, Chou VP, Johnston LC, McCormack AL, Johnston J, Langston JW, Di Monte DA (2006) Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol 60(2):256\u2013260","journal-title":"Ann Neurol"},{"issue":"4","key":"931_CR59","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mds.1149","volume":"16","author":"EC Maratos","year":"2001","unstructured":"Maratos EC, Jackson MJ, Pearce RK, Jenner P (2001) Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord 16(4):631\u2013641","journal-title":"Mov Disord"},{"issue":"6","key":"931_CR60","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1037\/h0077230","volume":"90","author":"JF Marshall","year":"1976","unstructured":"Marshall JF, Levitan D, Stricker EM (1976) Activation-induced restoration of sensorimotor functions in rats with dopamine-depleting brain lesions. J Comp Physiol Psychol 90(6):536\u2013546","journal-title":"J Comp Physiol Psychol"},{"issue":"3","key":"931_CR62","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0304-3940(00)01701-8","volume":"297","author":"KS McNaught","year":"2001","unstructured":"McNaught KS, Jenner P (2001) Proteasomal function is impaired in substantia nigra in Parkinson\u2019s disease. Neurosci Lett 297(3):191\u2013194","journal-title":"Neurosci Lett"},{"issue":"8","key":"931_CR61","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/35086067","volume":"2","author":"KS McNaught","year":"2001","unstructured":"McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P (2001) Failure of the ubiquitin-proteasome system in Parkinson\u2019s disease. Nat Rev Neurosci 2(8):589\u2013594","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"931_CR63","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/exnr.2002.8050","volume":"179","author":"KS McNaught","year":"2003","unstructured":"McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson\u2019s disease. Exp Neurol 179(1):38\u201346","journal-title":"Exp Neurol"},{"issue":"1","key":"931_CR64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ana.20186","volume":"56","author":"KS McNaught","year":"2004","unstructured":"McNaught KS, Perl DP, Brownell AL, Olanow CW (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson\u2019s disease. Ann Neurol 56(1):149\u2013162","journal-title":"Ann Neurol"},{"key":"931_CR65","doi-asserted-by":"crossref","unstructured":"McNaught KS, Olanow CW (2006) Proteasome inhibitor-induced model of Parkinson\u2019s disease. Ann Neurol 60:243\u2013247","DOI":"10.1002\/ana.20936"},{"issue":"3","key":"931_CR66","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1385\/MN:28:3:209","volume":"28","author":"W Meissner","year":"2003","unstructured":"Meissner W, Prunier C, Guilloteau D, Chalon S, Gross CE, Bezard E (2003) Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson\u2019s disease. Mol Neurobiol 28(3):209\u2013218","journal-title":"Mol Neurobiol"},{"issue":"1\u20132","key":"931_CR67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.brainresbull.2004.10.011","volume":"68","author":"C Monville","year":"2005","unstructured":"Monville C, Torres EM, Dunnett SB (2005) Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res Bull 68(1\u20132):16\u201323","journal-title":"Brain Res Bull"},{"issue":"1","key":"931_CR68","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1006\/exnr.2002.7976","volume":"177","author":"A Mura","year":"2002","unstructured":"Mura A, Mintz M, Feldon J (2002) Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system. Exp Neurol 177(1):252\u2013264","journal-title":"Exp Neurol"},{"issue":"26","key":"931_CR69","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/0024-3205(85)90146-8","volume":"36","author":"WJ Nicklas","year":"1985","unstructured":"Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36(26):2503\u20132508","journal-title":"Life Sci"},{"issue":"2","key":"931_CR70","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","volume":"27","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, Serbanescu A, Deckers F, Russ H (2004) Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 27(2):58\u201362","journal-title":"Clin Neuropharmacol"},{"issue":"5 Pt 2","key":"931_CR71","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995","volume":"15","author":"M Olsson","year":"1995","unstructured":"Olsson M, Nikkhah G, Bentlage C, Bjorklund A (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15(5 Pt 2):3863\u20133875","journal-title":"J Neurosci"},{"issue":"1\u20132","key":"931_CR72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-8993(94)90796-X","volume":"662","author":"SM Papa","year":"1994","unstructured":"Papa SM, Engber TM, Kask AM, Chase TN (1994) Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662(1\u20132):69\u201374","journal-title":"Brain Res"},{"key":"931_CR73","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.gene.2005.06.040","volume":"361","author":"J Park","year":"2005","unstructured":"Park J, Kim SY, Cha GH, Lee SB, Kim S, Chung J (2005) Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. Gene 361:133\u2013139","journal-title":"Gene"},{"issue":"3","key":"931_CR74","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0306-4522(91)90080-8","volume":"44","author":"C Pifl","year":"1991","unstructured":"Pifl C, Schingnitz G, Hornykiewicz O (1991) Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44(3):591\u2013605","journal-title":"Neuroscience"},{"issue":"5","key":"931_CR75","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/0006-2952(83)90589-0","volume":"32","author":"C Reavill","year":"1983","unstructured":"Reavill C, Jenner P, Marsden CD (1983) Differentiation of dopamine agonists using drug-induced rotation in rats with unilateral or bilateral 6-hydroxydopamine destruction of ascending dopamine pathways. Biochem Pharmacol 32(5):865\u2013870","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"931_CR76","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbr.2005.08.007","volume":"166","author":"RM Ridley","year":"2006","unstructured":"Ridley RM, Cummings RM, Leow-Dyke A, Baker HF (2006) Neglect of memory after dopaminergic lesions in monkeys. Behav Brain Res 166(2):253\u2013262","journal-title":"Behav Brain Res"},{"issue":"6","key":"931_CR77","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/j.1471-4159.1990.tb05809.x","volume":"55","author":"AH Schapira","year":"1990","unstructured":"Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD (1990) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson\u2019s disease. J Neurochem 55(6):2142\u20132145","journal-title":"J Neurochem"},{"issue":"2","key":"931_CR78","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.20934","volume":"60","author":"AH Schapira","year":"2006","unstructured":"Schapira AH, Cleeter MW, Muddle JR, Workman JM, Cooper JM, King RH (2006) Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol 60(2):253\u2013255","journal-title":"Ann Neurol"},{"issue":"2\u20133","key":"931_CR79","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","volume":"50","author":"RK Schwarting","year":"1996","unstructured":"Schwarting RK, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50(2\u20133):275\u2013331","journal-title":"Prog Neurobiol"},{"issue":"6","key":"931_CR80","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.870120616","volume":"12","author":"LA Smith","year":"1997","unstructured":"Smith LA, Gordin A, Jenner P, Marsden CD (1997) Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov Disord 12(6):935\u2013945","journal-title":"Mov Disord"},{"issue":"12","key":"931_CR81","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/mds.10588","volume":"18","author":"K Steece-Collier","year":"2003","unstructured":"Steece-Collier K, Collier TJ, Danielson PD, Kurlan R, Yurek DM, Sladek JR Jr (2003) Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Mov Disord 18(12):1442\u20131454","journal-title":"Mov Disord"},{"key":"931_CR82","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-201X.1971.tb11001.x","volume":"367","author":"U Ungerstedt","year":"1971","unstructured":"Ungerstedt U (1971a) Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:95\u2013122","journal-title":"Acta Physiol Scand Suppl"},{"key":"931_CR83","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","volume":"367","author":"U Ungerstedt","year":"1971","unstructured":"Ungerstedt U (1971b) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:69\u201393","journal-title":"Acta Physiol Scand Suppl"},{"issue":"1","key":"931_CR84","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00441-004-0937-z","volume":"318","author":"VN Uversky","year":"2004","unstructured":"Uversky VN (2004) Neurotoxicant-induced animal models of Parkinson\u2019s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 318(1):225\u2013241","journal-title":"Cell Tissue Res"},{"issue":"11","key":"931_CR85","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","volume":"21","author":"NP Visanji","year":"2006","unstructured":"Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, Fox SH (2006) Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson\u2019s disease. Mov Disord 21(11):1879\u20131891","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"931_CR86","first-page":"167","volume":"89","author":"IQ Whishaw","year":"1997","unstructured":"Whishaw IQ, Woodward NC, Miklyaeva E, Pellis SM (1997) Analysis of limb use by control rats and unilateral DA-depleted rats in the Montoya staircase test: movements, impairments and compensatory strategies. Behav Brain Res 89(1\u20132):167\u2013177","journal-title":"Behav Brain Res"},{"issue":"2","key":"931_CR87","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/exnr.1998.6916","volume":"155","author":"C Winkler","year":"1999","unstructured":"Winkler C, Bentlage C, Nikkhah G, Samii M, Bjorklund A (1999) Intranigral transplants of GABA-rich striatal tissue induce behavioral recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants. Exp Neurol 155(2):165\u2013186","journal-title":"Exp Neurol"},{"issue":"2","key":"931_CR88","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.20932","volume":"60","author":"BY Zeng","year":"2006","unstructured":"Zeng BY, Bukhatwa S, Hikima A, Rose S, Jenner P (2006) Reproducible nigral cell death after systemic proteasomal inhibitor administration to rats. Ann Neurol 60(2):248\u2013252","journal-title":"Ann Neurol"},{"issue":"1","key":"931_CR89","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0006-8993(91)90553-8","volume":"556","author":"FC Zhou","year":"1991","unstructured":"Zhou FC, Bledsoe S, Murphy J (1991) Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 556(1):108\u2013116","journal-title":"Brain Res"},{"issue":"4","key":"931_CR90","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/cne.20305","volume":"478","author":"C Zhu","year":"2004","unstructured":"Zhu C, Vourc\u2019h P, Fernagut PO, Fleming SM, Lacan S, Dicarlo CD, Seaman RL, Chesselet MF (2004) Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J Comp Neurol 478(4):418\u2013426","journal-title":"J Comp Neurol"},{"issue":"55","key":"931_CR91","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.177.4055.1211","volume":"177","author":"MJ Zigmond","year":"1972","unstructured":"Zigmond MJ, Stricker EM (1972) Deficits in feeding behavior after intraventricular injection of 6-hydroxydopamine in rats. Science 177(55):1211\u20131214","journal-title":"Science"},{"issue":"113","key":"931_CR92","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1126\/science.182.4113.717","volume":"182","author":"MJ Zigmond","year":"1973","unstructured":"Zigmond MJ, Stricker EM (1973) Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions. Science 182(113):717\u2013720","journal-title":"Science"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-007-0931-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-007-0931-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-007-0931-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T06:44:27Z","timestamp":1684046667000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-007-0931-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,25]]},"references-count":92,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["931"],"URL":"https:\/\/doi.org\/10.1007\/s00213-007-0931-8","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,25]]}}}